Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma

NCT05303519 is registered in ClinicalTrials.gov with Nuvation Bio Inc. as lead sponsor.

NCT NCT05303519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05303519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma
Lead sponsor
Nuvation Bio Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
June 5, 2023
Completion date
December 1, 2030
Enrollment
365 (estimated)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, grade iv, astrocytoma, idh-mutant, grade 2, astrocytoma, idh-mutant, grade 3, astrocytoma, idh-mutant, grade 4, glioma, idh1-mutant glioma, oligodendroglioma, oligodendroglioma, idh-mutant and 1p/19q-codeleted